3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
2
Gastrointestinal
1
Conditions
Mesothelioma, Malignant
2
Severe combined immunodeficiency with sensitivity to ionizing radiation
1
Interventions
pembrolizumab
26
Pemetrexed
26
Cisplatin
25
Nivolumab
22
Carboplatin
16
Paclitaxel
14
Gemcitabine
12
Ipilimumab
11
tislelizumab
8
durvalumab
8
Ramucirumab
8
Docetaxel
8
talazoparib
7
Fluorouracil
7
Radiotherapy
6
Capecitabine
6
tremelimumab
5
cobimetinib
5
atezolizumab
5
adavosertib
5
Radiosurgery
5
Cyclophosphamide
5
Bevacizumab
5
olaparib
4
avelumab
4
Temozolomide
4
Sunitinib
4
Specimen Handling
4
Platinum
4
PM 01183
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
amatuximab
×
Other solid neoplasm
×
Clear all
NCT00738582
2022-09-22
Amatuximab
Morphotek
Phase 2
Completed
89 enrolled
12 charts
NCT02357147
2020-03-17
ARTEMIS
Morphotek
Phase 2
Terminated
124 enrolled
10 charts